Anti-TAK1 antibody [EPR5984] - BSA and Azide free,Abcam,AB222394
ab222394 is the carrier-free version of ab109526 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Human
Application
ICC/IF, WB, IHC-P, Flow Cyt (Intra)
Platform ID
BAB987060450
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway (PubMed : 10094049, PubMed : 11460167, PubMed : 12589052, PubMed : 16845370, PubMed : 16893890, PubMed : 21512573, PubMed : 8663074, PubMed : 9079627). Plays an important role in the cascades of cellular responses evoked by changes in the environment (PubMed : 10094049, PubMed : 11460167, PubMed : 12589052, PubMed : 16845370, PubMed : 16893890, PubMed : 21512573, PubMed : 8663074, PubMed : 9079627). Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR) (PubMed : 16893890, PubMed : 9079627). Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7 (PubMed : 11460167, PubMed : 8663074). These MAP2Ks in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs); both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1) (PubMed : 11460167, PubMed : 12589052, PubMed : 8663074). Independently of MAP2Ks and p38 MAPKs, acts as a key activator of NF-kappa-B by promoting activation of the I-kappa-B-kinase (IKK) core complex (PubMed : 12589052, PubMed : 8663074). Mechanistically, recruited to polyubiquitin chains of RIPK2 and IKBKG/NEMO via TAB2/MAP3K7IP2 and TAB3/MAP3K7IP3, and catalyzes phosphorylation and activation of IKBKB/IKKB component of the IKK complex, leading to NF-kappa-B activation (PubMed : 10094049, PubMed : 11460167). In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B (PubMed : 16893890). Promotes TRIM5 capsid-specific restriction activity (PubMed : 21512573). Phosphorylates RIPK1 at 'Ser-321' which positively regulates RIPK1 interaction with RIPK3 to promote necroptosis but negatively regulates RIPK1 kinase activity and its interaction with FADD to mediate apoptosis (By similarity). Phosphorylates STING1 in response to cGAMP-activation, promoting association between STEEP1 and STING1 and STING1 translocation to COPII vesicles (PubMed : 37832545). See full target information MAP3K7
Category Paths
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.